Results 181 to 190 of about 2,243,647 (283)

Designing Tissue Function Through Embedded Bioprinting Architectures

Advanced Science, Volume 13, Issue 52, 18 September 2026.
Embedded bioprinting enables soft, cell‐dense constructs to be fabricated within supporting bath environments. This review introduces a function‐guided framework linking target tissue functions to architectural requirements, supporting bath selection, bioink design, printing dynamics, and validation assays.
Qi Li, Yifei Cao, Jiaxin Lin, Huayong Yang, Hongzhao Zhou   +4 more
wiley   +1 more source

Setting the record straight: Activity of gemcitabine monotherapy for breast cancer - Reply [PDF]

, 2004
Heinemann, Volker
core   +1 more source

Circular RNA hsa_circ_0003472 Promotes Pancreatic Ductal Adenocarcinoma Progression and Gemcitabine Resistance Via the mir-1253/ERCC1 Axis. [PDF]

Biol Proced Online
Xia C, Chen Y, Yin X, Zhu Y, Wang G, Chen D, Shen T, Yang X, Sun H, Zhu H.   +9 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma. [PDF]

Biomed Rep
Kidoikhammouan S, Mahalapbutr P, Ma-In P, Lert-Itthiporn W, Deenonpoe R, Suriya U, Wongkham S, Seubwai W.   +7 more
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

TGM2-P2RX7 loop promotes gemcitabine resistance in pancreatic cancer by modulating glutamine metabolism and mitophagy. [PDF]

Cell Death Discov
Ye K, Zhou S, Gong X, Zhu Z, Xiao M, Liang S.   +5 more
europepmc   +1 more source

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

Brain and Behavior, Volume 16, Issue 9, September 2026.
Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, driven by abnormal signaling pathways that promote growth and resistance to treatment. Conventional therapies are inadequate, highlighting the need for novel multitargeted approaches.
Mehrukh Zehravi, Md Abul Hassan, Md. Al Amin, Sherouk Hussein Sweilam, Jeetendra Kumar Gupta, Ramenani Hari Babu, Pericharla Venkata Narasimha Raju, Krishna Vamsi Kandimalla, Phanindra Erukulla, Patibandla Jahnavi, Rajeshwar Vodeti, Abdul Ajeed Mohathasim Billah, Safia Obaidur Rab, Sharuk L. Khan   +13 more
wiley   +1 more source

Mechanisms of gemcitabine resistance in pancreatic cancer [PDF]

, 2018
openaire   +1 more source

Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Radiotherapy remains a cornerstone of cancer treatment, while its efficacy is often limited by tumor radioresistance and the risk of normal tissue toxicity. Conventional preclinical models, including two‐dimensional (2D) cell cultures and murine xenografts, exhibit significant limitations in recapitulating human tumor ...
Yixian Zhu, Yawei Jiao, Jiao Xue, Xiaoli Lv, Songbing Qin   +4 more
wiley   +1 more source